Wall Street just turned bearish on this top-performing Nvidia stock

CoreWeave (CRWV) shares recently declined and received downgrades from Stifel and Mizuho, despite a nearly 300% surge since its IPO and a strategic $9 billion all-stock acquisition of Bitcoin miner Core Scientific (CORZ) to bolster its AI infrastructure and power capacity. Analysts, while acknowledging the long-term strategic value of the Core Scientific deal, cited "key near-term overhangs" and concerns that the stock's rapid appreciation has led to a more balanced risk-reward profile, prompting the downgrades even as both firms significantly raised their price targets.

Analysis

Despite a 299% surge since its March IPO, Wall Street sentiment on CoreWeave (CRWV) has turned cautious, evidenced by a recent 3.33% share price decline and downgrades from two key firms. Stifel downgraded the stock to 'Hold' and Mizuho to 'Neutral', citing valuation concerns after the rapid appreciation. This caution persists even as both firms significantly raised their price targets—Stifel to $115 from $75 and Mizuho to $150 from $70—acknowledging the company's strong position in AI infrastructure. The downgrades are attributed to a more balanced risk-reward profile and what Stifel terms "key near-term overhangs." These concerns overshadow the long-term strategic benefits of CoreWeave's planned $9 billion all-stock acquisition of Bitcoin miner Core Scientific (CORZ). Analysts agree this deal will vertically integrate the company, securing 1.3 gigawatts of power capacity and positioning it as a leading provider of high-performance computing infrastructure, but the immediate valuation pressure is the primary driver of the revised ratings.

Key Decisions for Investors

• Investors with significant gains from the 299% post-IPO run-up should consider the recent analyst downgrades as a signal that the risk/reward profile has become more balanced, potentially justifying trimming positions to realize profits.
• Prospective investors should exercise caution, as the stock's valuation is now a primary concern for analysts; it may be prudent to wait for a more favorable entry point or for clarity on the "near-term overhangs" associated with the Core Scientific acquisition.
• Monitor the execution and integration of the Core Scientific acquisition, as its success is critical to validating the long-term strategic rationale and supporting the stock's elevated valuation against the new, higher price targets.